Drug Manufacturers - Specialty & Generic
Compare Stocks
4 / 10Stock Comparison
INDV vs AVPT vs QLYS vs RBBN
Revenue, margins, valuation, and 5-year total return — side by side.
Software - Infrastructure
Software - Infrastructure
Telecommunications Services
INDV vs AVPT vs QLYS vs RBBN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Software - Infrastructure | Software - Infrastructure | Telecommunications Services |
| Market Cap | $4.94B | $2.23B | $3.34B | $472M |
| Revenue (TTM) | $1.29B | $444M | $685M | $826M |
| Net Income (TTM) | $251M | $47M | $201M | $31M |
| Gross Margin | 83.1% | 73.7% | 83.1% | 48.7% |
| Operating Margin | 33.3% | 9.6% | 33.7% | -0.7% |
| Forward P/E | 12.7x | 27.7x | 12.9x | 20.7x |
| Total Debt | $351M | $10M | $97M | $405M |
| Cash & Equiv. | $195M | $481M | $250M | $96M |
INDV vs AVPT vs QLYS vs RBBN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Indivior Pharmaceut… (INDV) | 100 | 990.0 | +890.0% |
| AvePoint, Inc. (AVPT) | 100 | 105.4 | +5.4% |
| Qualys, Inc. (QLYS) | 100 | 82.3 | -17.7% |
| Ribbon Communicatio… (RBBN) | 100 | 61.1 | -38.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INDV vs AVPT vs QLYS vs RBBN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INDV is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 281.7% 10Y total return vs QLYS's 267.2%
- Lower P/E (12.7x vs 20.7x)
- +244.9% vs AVPT's -40.0%
AVPT is the clearest fit if your priority is growth exposure.
- Rev growth 26.9%, EPS growth 193.8%, 3Y rev CAGR 21.8%
- 26.9% revenue growth vs RBBN's 1.3%
QLYS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.53
- Lower volatility, beta 0.53, Low D/E 17.3%, current ratio 1.41x
- Beta 0.53, current ratio 1.41x
- 29.4% margin vs RBBN's 3.8%
RBBN lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 26.9% revenue growth vs RBBN's 1.3% | |
| Value | Lower P/E (12.7x vs 20.7x) | |
| Quality / Margins | 29.4% margin vs RBBN's 3.8% | |
| Stability / Safety | Beta 0.53 vs RBBN's 1.49, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +244.9% vs AVPT's -40.0% | |
| Efficiency (ROA) | 19.1% ROA vs RBBN's 2.7%, ROIC 47.5% vs 2.1% |
INDV vs AVPT vs QLYS vs RBBN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
INDV vs AVPT vs QLYS vs RBBN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
QLYS leads in 1 of 6 categories
RBBN leads 1 • AVPT leads 1 • INDV leads 1 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
QLYS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INDV is the larger business by revenue, generating $1.3B annually — 2.9x AVPT's $444M. QLYS is the more profitable business, keeping 29.4% of every revenue dollar as net income compared to RBBN's 3.8%. On growth, AVPT holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.3B | $444M | $685M | $826M |
| EBITDAEarnings before interest/tax | $447M | $47M | $241M | $40M |
| Net IncomeAfter-tax profit | $251M | $47M | $201M | $31M |
| Free Cash FlowCash after capex | -$185M | $105M | $290M | $17M |
| Gross MarginGross profit ÷ Revenue | +83.1% | +73.7% | +83.1% | +48.7% |
| Operating MarginEBIT ÷ Revenue | +33.3% | +9.6% | +33.7% | -0.7% |
| Net MarginNet income ÷ Revenue | +19.4% | +10.5% | +29.4% | +3.8% |
| FCF MarginFCF ÷ Revenue | -14.3% | +23.6% | +42.4% | +2.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.2% | +26.0% | +9.8% | -10.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +81.6% | +3.6% | +10.1% | -33.3% |
Valuation Metrics
RBBN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 12.2x trailing earnings, RBBN trades at a 82% valuation discount to AVPT's 68.8x P/E. On an enterprise value basis, RBBN's 9.6x EV/EBITDA is more attractive than AVPT's 44.8x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $4.9B | $2.2B | $3.3B | $472M |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $1.8B | $3.2B | $781M |
| Trailing P/EPrice ÷ TTM EPS | 24.15x | 68.80x | 17.45x | 12.23x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.65x | 27.75x | 12.87x | 20.69x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.90x | — |
| EV / EBITDAEnterprise value multiple | 17.88x | 44.79x | 13.49x | 9.57x |
| Price / SalesMarket cap ÷ Revenue | 3.99x | 5.31x | 5.00x | 0.56x |
| Price / BookPrice ÷ Book value/share | — | 4.94x | 6.17x | 1.08x |
| Price / FCFMarket cap ÷ FCF | — | 27.32x | 10.98x | 18.13x |
Profitability & Efficiency
AVPT leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
QLYS delivers a 37.2% return on equity — every $100 of shareholder capital generates $37 in annual profit, vs $8 for RBBN. AVPT carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBBN's 0.90x. On the Piotroski fundamental quality scale (0–9), AVPT scores 6/9 vs INDV's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +10.2% | +37.2% | +7.9% |
| ROA (TTM)Return on assets | +19.1% | +6.3% | +19.1% | +2.7% |
| ROICReturn on invested capital | +3.4% | +11.4% | +47.5% | +2.1% |
| ROCEReturn on capital employed | +79.1% | +8.1% | +37.8% | +2.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | — | 0.02x | 0.17x | 0.90x |
| Net DebtTotal debt minus cash | $156M | -$471M | -$153M | $309M |
| Cash & Equiv.Liquid assets | $195M | $481M | $250M | $96M |
| Total DebtShort + long-term debt | $351M | $10M | $97M | $405M |
| Interest CoverageEBIT ÷ Interest expense | 10.88x | — | — | -0.02x |
Total Returns (Dividends Reinvested)
INDV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INDV five years ago would be worth $36,837 today (with dividends reinvested), compared to $3,899 for RBBN. Over the past 12 months, INDV leads with a +244.9% total return vs AVPT's -40.0%. The 3-year compound annual growth rate (CAGR) favors AVPT at 32.6% vs QLYS's -6.3% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +10.8% | -21.9% | -27.5% | -7.2% |
| 1-Year ReturnPast 12 months | +244.9% | -40.0% | -25.6% | -11.8% |
| 3-Year ReturnCumulative with dividends | +97.0% | +133.0% | -17.7% | +1.9% |
| 5-Year ReturnCumulative with dividends | +268.4% | +1.7% | -3.1% | -61.0% |
| 10-Year ReturnCumulative with dividends | +281.7% | +5.5% | +267.2% | -68.2% |
| CAGR (3Y)Annualised 3-year return | +25.4% | +32.6% | -6.3% | +0.6% |
Risk & Volatility
Evenly matched — INDV and QLYS each lead in 1 of 2 comparable metrics.
Risk & Volatility
QLYS is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than RBBN's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INDV currently trades 96.6% from its 52-week high vs AVPT's 51.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 1.06x | 0.53x | 1.49x |
| 52-Week HighHighest price in past year | $41.00 | $20.25 | $155.47 | $4.29 |
| 52-Week LowLowest price in past year | $10.63 | $8.83 | $74.51 | $1.80 |
| % of 52W HighCurrent price vs 52-week peak | +96.6% | +51.0% | +61.1% | +62.7% |
| RSI (14)Momentum oscillator 0–100 | 79.6 | 54.1 | 54.2 | 54.3 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 1.6M | 773K | 879K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: INDV as "Buy", AVPT as "Buy", QLYS as "Hold", RBBN as "Buy". Consensus price targets imply 69.6% upside for AVPT (target: $18) vs 12.8% for INDV (target: $45).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $44.67 | $17.50 | $134.30 | $3.50 |
| # AnalystsCovering analysts | 3 | 12 | 48 | 8 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +2.2% | +5.5% | +1.9% |
QLYS leads in 1 of 6 categories (Income & Cash Flow). RBBN leads in 1 (Valuation Metrics). 1 tied.
INDV vs AVPT vs QLYS vs RBBN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INDV or AVPT or QLYS or RBBN a better buy right now?
For growth investors, AvePoint, Inc.
(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus 1. 3% for Ribbon Communications Inc. (RBBN). Ribbon Communications Inc. (RBBN) offers the better valuation at 12. 2x trailing P/E (20. 7x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INDV or AVPT or QLYS or RBBN?
On trailing P/E, Ribbon Communications Inc.
(RBBN) is the cheapest at 12. 2x versus AvePoint, Inc. at 68. 8x. On forward P/E, Indivior Pharmaceuticals Inc is actually cheaper at 12. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — INDV or AVPT or QLYS or RBBN?
Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +268.
4%, compared to -61. 0% for Ribbon Communications Inc. (RBBN). Over 10 years, the gap is even starker: INDV returned +281. 7% versus RBBN's -68. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INDV or AVPT or QLYS or RBBN?
By beta (market sensitivity over 5 years), Qualys, Inc.
(QLYS) is the lower-risk stock at 0. 53β versus Ribbon Communications Inc. 's 1. 49β — meaning RBBN is approximately 181% more volatile than QLYS relative to the S&P 500. On balance sheet safety, AvePoint, Inc. (AVPT) carries a lower debt/equity ratio of 2% versus 90% for Ribbon Communications Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — INDV or AVPT or QLYS or RBBN?
By revenue growth (latest reported year), AvePoint, Inc.
(AVPT) is pulling ahead at 26. 9% versus 1. 3% for Ribbon Communications Inc. (RBBN). On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108. 3% year-over-year, compared to 17. 0% for Qualys, Inc.. Over a 3-year CAGR, AVPT leads at 21. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INDV or AVPT or QLYS or RBBN?
Qualys, Inc.
(QLYS) is the more profitable company, earning 29. 6% net margin versus 4. 7% for Ribbon Communications Inc. — meaning it keeps 29. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QLYS leads at 33. 2% versus 2. 4% for RBBN. At the gross margin level — before operating expenses — QLYS leads at 82. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INDV or AVPT or QLYS or RBBN more undervalued right now?
On forward earnings alone, Indivior Pharmaceuticals Inc (INDV) trades at 12.
7x forward P/E versus 27. 7x for AvePoint, Inc. — 15. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVPT: 69. 6% to $17. 50.
08Which pays a better dividend — INDV or AVPT or QLYS or RBBN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INDV or AVPT or QLYS or RBBN better for a retirement portfolio?
For long-horizon retirement investors, Qualys, Inc.
(QLYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53), +267. 2% 10Y return). Both have compounded well over 10 years (QLYS: +267. 2%, RBBN: -68. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INDV and AVPT and QLYS and RBBN?
These companies operate in different sectors (INDV (Healthcare) and AVPT (Technology) and QLYS (Technology) and RBBN (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INDV is a small-cap quality compounder stock; AVPT is a small-cap high-growth stock; QLYS is a small-cap deep-value stock; RBBN is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.